Learn More About genTRU-breast™

Why It Matters

More than 38 million U.S. women have dense breast tissue, which can both increase breast cancer risk and make cancers more difficult to detect through mammography alone.

As awareness grows, more women and healthcare providers are seeking additional information to help guide screening decisions.

Why RNA?

Unlike many blood-based approaches that focus on cell-free DNA, Mammogen's platform analyzes cell-free RNA (cfRNA), which may provide insight into active biological processes occurring in real time.

Mammogen's proprietary dual-source cfRNA™ approach captures both host-response and tumor-associated signals to support earlier detection opportunities.

Built on Evidence

• Up to 99% sensitivity in Stage I breast cancer using real-time qPCR technology*
• Peer-reviewed scientific validation
• Presented at SABCS
• Prospective clinical trial underway

Based on internal validation data. Ongoing clinical studies may yield different results.

Current Status

genTRU-breast™ is currently in clinical development and is advancing through prospective clinical validation and a CLIA-enabled commercialization pathway.

99% Sensitivity

Achieved sensitivity in Stage I breast cancer of up to 99% using real-time qPCR assay technology.

Peer-Reviewed Science

Published research supporting assay performance, robustness, and reproducibility across multiple development stages.

SABCS Validation

Presented and validated before leading breast cancer experts at the San Antonio Breast Cancer Symposium (SABCS).

Clinical Development

Advancing prospective clinical validation designed to support commercialization and clinical integration.